JWH-018

# Research Output: JWH-018

## Chemical Identity

**PubChem CID:** 10382701 (api_verified via get_pubchem_compound)
**IUPAC name:** naphthalen-1-yl-(1-pentylindol-3-yl)methanone
**Systematic name (brief):** 1-pentyl-3-(1-naphthoyl)indole
**Common synonyms:** AM-678, (1-Pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone
**Molecular formula:** C₂₄H₂₃NO
**Molecular weight:** 341.4 g/mol
**InChIKey:** JDNLPKCAXICMBW-UHFFFAOYSA-N

The brief's seed data lists no molecular formula, weight, SMILES, InChIKey, or PubChem CID — all of these are now confirmed from PubChem. The IUPAC name in the brief ("naphthalen-1-yl-(1-pentylindol-3-yl)methanone") is consistent with PubChem's returned IUPAC name.

**Stereochemistry:** JWH-018 contains no stereocenters; it is an achiral molecule. No active isomers apply.

**Physical properties:** JWH-018 is a lipophilic compound; no reliable published experimental melting point data was retrieved via API search. PubChem entry does not report a melting point in the structured fields returned. It is soluble in ethanol and non-polar organic solvents (acetone, ethyl acetate) but poorly water-soluble [Ref 35, web]. Specific logP, pKa, and water solubility values are not available from peer-reviewed sources identified in this search.

**No discrepancies** between the brief seed data and published sources for the identifiers now confirmed.

---

## Pharmacology

### Receptor Binding

JWH-018 is a potent cannabinoid receptor agonist with high affinity at both CB1 and CB2 receptors. Reported binding affinities from competition radioligand assays using [³H]CP-55,940:

- **CB1 Ki ≈ 9.00 ± 5.00 nM** [Ref 35, web-retrieved; consistent with data reported in Ref 12]
- **CB2 Ki ≈ 2.94 ± 2.65 nM** [Ref 35, web-retrieved]

These values indicate CB2 selectivity relative to CB1, and both values represent 5–10-fold higher affinity than Δ⁹-THC at CB1 (Ki ≈ 40–80 nM). An early structural pharmacology study by Chin et al. (1999 [Ref 12]) reported a JWH-018 Ki of ~9.8 nM at wild-type CB1 in CHO cells using radioligand competition assays, consistent with the above values.

### Full Agonism vs. THC Partial Agonism

A critical pharmacological distinction: JWH-018 functions as a **full agonist** at CB1, whereas Δ⁹-THC is a **partial agonist**. Brents et al. (2011 [Ref 1]) demonstrated that JWH-018 and several of its hydroxylated metabolites stimulate G-proteins in [³⁵S]GTPγS binding assays with equal or greater efficacy than THC, and that JWH-018, M2, M3, and M5 metabolites produced **full CB1R agonist** levels of activation. This full agonism, combined with the absence of CBD (which attenuates CB1 psychotomimetic effects in cannabis), is widely cited as the mechanistic basis for JWH-018's more severe adverse effect profile relative to cannabis (Brents et al. 2011 [Ref 1]; van Amsterdam et al. 2015 [Ref 25]).

### Mechanism of Action

JWH-018 acts as a full agonist at cannabinoid CB1 and CB2 G-protein-coupled receptors. CB1 receptors are primarily expressed in the CNS (striatum, hippocampus, cerebellum, prefrontal cortex); CB2 receptors are primarily peripheral (immune tissues, spleen). Agonism of CB1 in the mesolimbic pathway acutely increases dopaminergic transmission selectively in the nucleus accumbens shell, providing the neurobiological basis for reinforcing properties and euphoria (Pintori et al. 2021 [Ref 15]).

The CB1 receptor is a Gi/o-coupled GPCR; activation inhibits adenylyl cyclase, modulates ion channel activity, and activates ERK/MAPK signaling. JWH-018's full CB1 efficacy means it produces maximal Gα activation, distinguishing it from partial agonists like THC (Brents et al. 2011 [Ref 1]; Chimalakonda et al. 2012 [Ref 2]).

JWH-018 was originally synthesized as a structural hybrid of Δ⁹-THC and the prototypic aminoalkylindole WIN55,212-2. While THC uses electrostatic interactions at CB1 helix-3 residues, JWH-018 (like WIN55,212-2) primarily uses aromatic stacking interactions. The third transmembrane helix of CB1 plays a role in aminoalkylindole selectivity, as demonstrated in chimeric CB1/CB2 receptor studies (Chin et al. 1999 [Ref 12]; Howlett et al. 2021 [Ref 5]).

### Active Metabolites

JWH-018 hydroxylated metabolites are pharmacologically active — a critical distinction from most drugs. Brents et al. (2011 [Ref 1]) showed that five monohydroxylated JWH-018 metabolites (M1–M5) all retained high CB1R affinity (Ki values lower than or equivalent to THC). M2, M3, and M5 are full CB1R agonists; M1 is a partial agonist. Only the carboxy metabolite (M6) is pharmacologically inactive at CB1R. This active metabolite profile — unusual in pharmacology — may extend and intensify the duration of effect and contribute to the atypical adverse effect severity seen with K2/Spice use (Brents et al. 2011 [Ref 1]).

### Pharmacokinetics

**Route of administration:** Primarily smoked (inhaled). The brief's seed data lists smoked as both primary and only known ROA. No intranasal, oral, or IV human PK studies for JWH-018 are available in published literature.

**CYP metabolism:** JWH-018 undergoes extensive hepatic oxidative metabolism. Primary CYP enzymes:
- **CYP2C9** and **CYP1A2** are the major P450s responsible for JWH-018 oxidation (Chimalakonda et al. 2012 [Ref 2]; Chimalakonda et al. 2013 [Ref 3]; Stout & Cimino 2014 [Ref 4])
- Kinetic parameters in human liver microsomes: Km = 0.81–7.3 µM; Vmax = 0.0053–2.7 nmol product/min/nmol protein [Ref 2]
- CYP2C19, 2D6, 2E1, 3A4 contribute minimally (fm < 0.2) [Ref 2]
- UDP-glucuronosyltransferases (UGTs) contribute to secondary metabolism [Ref 4]

**Implication:** CYP2C9 polymorphisms (slow metabolizers) could increase JWH-018 exposure and toxicity risk. CYP1A2 inducers (e.g., smoking tobacco) may accelerate clearance (Chimalakonda et al. 2013 [Ref 3]).

**Urinary metabolites:** Identified via LC-MS/MS in human urine post-exposure:
- 6-OH-JWH-018 (6-hydroxylation)
- N-alkyl-OH metabolite (N-pentyl terminal hydroxylation)
- N-pentanoic acid metabolite (terminal carboxylation)
(ElSohly et al. 2011 [Ref 14]; Chimalakonda et al. 2012 [Ref 2])

**Half-life:** The brief states 5 days for tolerance half-life; no human PK half-life data from controlled studies was identified in published literature. The tolerance half-life reflects receptor-level adaptation, not plasma half-life. No published plasma half-life for JWH-018 in humans was retrievable.

**⚠ FLAG:** The seed data's tolerance half-life of "5 days" and full reset of "1.5 weeks" are not directly supported by any human PK study found in this search. These likely derive from anecdotal reports or cross-species extrapolation. The animal tolerance data from Tai et al. (2015 [Ref 22]) shows tolerance to hypothermia persisting at 14 days post-exposure in mice, which could inform this estimate but does not directly confirm it.

---

## History

### Synthesis and Origins

JWH-018 was synthesized by **John W. Huffman**, an organic chemist at Clemson University (Clemson, SC), as part of a NIDA-funded research program to develop tools for probing the endocannabinoid system (Howlett, Thomas & Huffman 2021 [Ref 5]; web sources [Ref 36]).

The JWH designation stands for John W. Huffman's initials; JWH-018 was the 18th compound in his numbered series. Huffman's group produced over 450 synthetic cannabinoid compounds designed to systematically vary structural features and establish structure-activity relationships (SAR) at CB1 and CB2 receptors [Ref 36].

JWH-018 is a **naphthoylindole** — structurally derived from a computational merging of the THC pharmacophore with the aminoalkylindole WIN55,212-2 (Howlett et al. 2021 [Ref 5]). The synthesis involves Friedel-Crafts acylation at the C3 position of indole followed by N-alkylation. Huffman synthesized JWH-018 in the **early-to-mid 1990s** for basic receptor pharmacology research with no anticipated recreational application [Refs 5, 36].

**Key Huffman publication:** The 2021 review by Howlett, Thomas & Huffman [Ref 5] is an authoritative account by the original researchers, documenting the scientific context, CB1/CB2 pharmacology, and the subsequent diversion of JWH-018 into illicit markets.

⚠ **FLAG:** The original 1994/1995 primary synthesis paper by Huffman et al. (likely in Journal of Medicinal Chemistry) was not retrievable via PubMed or OpenAlex API. The generation agent should note this is based on the 2021 review and web sources, not the primary publication.

### Discovery in Spice/K2 Products

JWH-018 remained obscure in academic literature until it was **identified as an active ingredient in commercial "Spice" herbal incense products**:
- **December 2008:** German and Austrian forensic chemists first identified JWH-018 in Spice products (Dresen, Ferreírós, Pütz, Westphal, Zimmermann & Auwärter 2010 [Ref 13])
- Monitoring of 140+ herbal mixture samples from June 2008–September 2009 revealed widespread JWH-018 use and rapid compositional changes in response to prohibition [Ref 13]

### Regulatory History

| Jurisdiction | Action | Date |
|---|---|---|
| Germany | Banned under Narcotics Law (JWH-018, CP-47,497 homologues) | January 2009 |
| UK | Class B under Misuse of Drugs Act 1971 | 23 December 2009 |
| USA (DEA) | Emergency Schedule I temporary placement | 1 March 2011 |
| USA (FDASIA) | Permanent Schedule I via Food and Drug Administration Safety and Innovation Act | 9 July 2012 |
| Australia | Criminal Code Regulation listing (44 substances) | April 2014 |
| Canada | Controlled via 3-(1-Naphthoyl)indole generic definition in CDSA Schedule II | Year unspecified |

[Refs 29, 30, 37, web sources]

Germany's early scheduling triggered rapid market substitution with JWH-073 and other analogs within weeks [Ref 13]. The EMCDDA began monitoring synthetic cannabinoids through its EU Early Warning System in 2008, with JWH-018 as the first identified compound [Ref 37].

---

## Subjective Effects

### Published Controlled Human Studies (Only Two Exist)

**⚠ IMPORTANT:** Only two placebo-controlled human administration studies of JWH-018 have been published, both from the Maastricht University group.

**Study 1 — Theunissen et al. (2018 [Ref 32]):** Phase 1, placebo-controlled, pilot study. Recruited healthy volunteers and administered JWH-018 at low doses (route described as inhalation via smoking mixtures). Key findings: cognitive and psychomotor impairment was detectable even when subjective intoxication ratings were low. This dissociation between objective impairment and subjective "high" is clinically significant.

**Study 2 — Theunissen et al. (2021 [Ref 20]):** Follow-up study in recreational cannabis users demonstrating representative levels of intoxication. JWH-018 caused significant cognitive and psychomotor impairment at doses achieving meaningful intoxication. The abstract notes that earlier work showed impairment even with low subjective intoxication.

**NCT06044415** (Maastricht University): A registered study titled "Brain Activity Under the Influence of JWH" (status: UNKNOWN), examining neurotransmission during JWH intoxication.

### Animal-Model Derived Effects (Tetrad Profile in Mice)

The cannabinoid tetrad battery in rodents — antinociception, hypothermia, catalepsy, and suppression of locomotor activity — has been extensively characterized for JWH-018 (Wiley, Marusich & Huffman 2014 [Ref 6]; Wiley, Marusich & Thomas 2017 [Ref 7]). JWH-018 produces all four tetrad effects at doses lower than THC, reflecting its higher CB1 affinity and full agonist efficacy. All tetrad effects are blocked by the CB1 antagonist AM251 (Vigolo et al. 2015 [Ref 23]).

At high doses in mice, JWH-018 causes **seizures, myoclonia, and hyperreflexia** — effects not seen with THC (Vigolo et al. 2015 [Ref 23]; Wilson et al. 2019 [Ref 21]).

### Reported Human Effects (Non-Controlled)

The following effects are documented in clinical case reports, ED data, and systematic reviews. They are **not from controlled dose-response studies** and should be labeled as such.

**Cannabis-like effects reported by users:**
- Euphoria, relaxation, altered sensory perception, increased appetite, sedation
- Effects described as similar to cannabis but often more intense and with faster onset
- Music enhancement, time distortion

**Atypical/adverse effects more common than cannabis:**
- Tachycardia (documented in 37–77% of ED presentations) [Ref 10]
- Agitation (16–41% of ED presentations) [Ref 10]
- Nausea/vomiting (13–94% of ED presentations) [Ref 10]
- Anxiety, panic attacks [Ref 1]
- Paranoia, psychosis [Refs 11, 25]
- Hypertension, hallucinations, seizures [Ref 1]

The Every-Palmer (2011 [Ref 11]) study was the first to systematically examine JWH-018 and psychosis in a psychiatric population.

### Duration Data (Smoked Route)

The brief's duration data (onset 5–10 min, peak 60–90 min, offset 5–10 min, aftereffects 60–90 min, total 1–2 hours) is consistent with what would be expected for a smoked CB1 agonist, and aligns with general synthetic cannabinoid descriptions in the reviewed literature. No controlled human pharmacokinetic study was found that precisely characterizes these timing parameters for JWH-018 specifically. **⚠ FLAG for human review:** Duration data should be treated as plausible class-level estimates, not JWH-018-specific verified values.

---

## Safety & Toxicity

### LD50 / Lethal Dose

No published LD50 data for JWH-018 in any species was found via PubMed or OpenAlex searches. **⚠ FLAG: The seed data states "exact toxic dosage is unknown" — confirmed. No LD50 value exists in published literature for JWH-018.**

### In Vitro Cytotoxicity

Koller et al. (2013 [Ref 19]) assessed JWH-018 in human cell lines:
- Membrane damage observed in buccal (TR146) and breast (MCF-7) cells at ≥75–100 µM — concentrations far above those expected in body fluids of users
- No mitochondrial damage, protein synthesis, or lysosomal toxicity detected
- Anti-estrogenic effects at 2.1–23.0 µM
- No estrogenic activity in bone marrow cells
- No cytokine release effects in LPS-stimulated PBMCs (except for other JWH compounds at high concentrations)
- Authors note that genotoxic effects may be relevant at epithelial concentrations even if serum levels are lower

### Serious Adverse Events

From the systematic review of ~4,000 cases (Tait et al. 2016 [Ref 10]):

**Major complications:**
- Cardiovascular events: myocardial infarction, ischemic stroke, thromboembolism
- Acute kidney injury (AKI)
- Generalized tonic-clonic seizures
- Psychiatric: first-episode psychosis, paranoia, self-harm/suicidal ideation
- Hyperemesis

**Most common presentations (typically self-limiting):**
- Tachycardia (~37–77%)
- Agitation (~16–41%)
- Nausea (~13–94%)
- Resolution with symptomatic care typically within 8 hours

**Deaths:** At least 26 deaths associated with SC use documented across 106 studies [Ref 10]. Attribution is complicated by polysubstance use in most cases.

### Seizure Risk

JWH-018 produces convulsions in mice via CB1 full agonism; more potent convulsant than pentylenetetrazol (PTZ) (Wilson et al. 2019 [Ref 21]). **Critically:** Benzodiazepines failed to attenuate JWH-018-induced convulsions in mice (while PTZ convulsions were blocked by diazepam). This suggests standard seizure management protocols may be inadequate for JWH-018-induced seizures [Ref 21]. CB1 antagonists (rimonabant) or THC pre-treatment did block JWH-018-induced convulsions [Ref 21].

### Psychosis Risk

JWH-018 is a full CB1 agonist with no CBD component in Spice preparations. Van Amsterdam et al. (2015 [Ref 25]) review specifically addresses why SCRAs have higher psychosis-inducing potential than cannabis: full agonism + no CBD. Every-Palmer (2011 [Ref 11]) documented psychosis association in a psychiatric case series; van Amsterdam et al. confirm the class-level risk. Satodiya & Palekar (2020 [Ref 27]) report persistent negative schizophrenia symptoms following SC use.

### Cardiovascular Toxicity

Tachycardia is the most consistently reported cardiovascular effect across ED case series [Ref 10]. Myocardial infarction and stroke are documented but rare [Ref 10]. The mechanism is not fully characterized but likely involves CB1-mediated sympathetic activation (Fattore & Fratta 2011 [Ref 9]).

### Hyperemesis / CHS

Cannabinoid hyperemesis syndrome has been reported with both cannabis and synthetic cannabinoids including JWH-018. Richards et al. (2018) identified hot-shower behavior and topical capsaicin treatment in CHS cases involving synthetic cannabinoids. The syndrome has a genetic susceptibility component involving CYP2C9, dopamine genes, and TRPV1 receptors (Russo & Whiteley 2024).

### Dose Sensitivity

The brief flags "dose sensitivity" as a concern. JWH-018 has a steep dose-response curve due to full agonism; small increases in dose may produce disproportionately large effects. The absence of CBD buffering (in Spice products) removes a natural safety margin present in cannabis. **⚠ FLAG:** No human dose-response safety data is published.

---

## Harm Reduction

### General Principles (Class-Level Evidence)

No JWH-018-specific harm reduction guidelines are published. The following derive from synthetic cannabinoid class evidence:

**Testing:** Standard cannabis immunoassays do not reliably detect JWH-018 (Barnes et al. 2014 [Ref 38]). Specialized ELISA or LC-MS/MS methods are required (ElSohly et al. 2011 [Ref 14]). No colorimetric spot test (Marquis, Mecke, etc.) has been validated for JWH-018 identification in published literature retrieved in this search.

**Dosing risks:** JWH-018 is applied to plant material in products of variable concentration; the dose in any given smoked portion is highly unpredictable (Dresen et al. 2010 [Ref 13]). Product composition changed frequently in response to prohibition. Harm reduction strongly implies: never assume a consistent dose between batches.

**Emergency management (class-level):** Per Tait et al. (2016 [Ref 10]):
- Most presentations resolve with symptomatic care (IV fluids, benzodiazepines, antiemetics)
- Inpatient care often not required for mild presentations
- **Important caveat:** Benzodiazepines may NOT be effective for JWH-018-induced seizures specifically (Wilson et al. 2019 [Ref 21]) — this conflicts with standard SC toxicity guidelines; needs clinical note

**Contraindications from literature (class-level):**
- Personal or family history of psychosis / schizophrenia spectrum disorders [Refs 11, 25]
- Adolescents / young adults (higher vulnerability to cannabis-induced psychosis) [Ref 25]
- CYP2C9 slow metabolizers (impaired elimination) [Ref 3]
- Concurrent CNS depressant use

---

## Tolerance & Dependence

### Tolerance Development

Tai et al. (2015 [Ref 22]) demonstrated in mice:
- Repeated daily JWH-018 (3 mg/kg/day × 5 days) produces **tolerance to hypothermic effects** but not locomotor suppression
- Tolerance persists at least **14 days** after the last dose
- Mechanism: brain-region-specific CB1R downregulation and desensitization — reduced CB1R expression and function in hypothalamus, but NOT in cortex
- JWH-018 produces stronger/faster tolerance than THC, consistent with higher intrinsic efficacy

**Cross-tolerance:** Mice with THC history showed cross-tolerance to both JWH-018 and JWH-073. Cross-tolerance is bidirectional and classified under cannabinoid cross-tolerance [Ref 22].

Wilson et al. (2019 [Ref 21]) demonstrated **tolerance to JWH-018 convulsant effects** with repeated sub-threshold dosing; no cross-tolerance to PTZ (confirming the CB1-specific mechanism).

**Human data:** Gunderson et al. (2012 [Ref 18]) documented three cases of experienced marijuana users with cannabis dependence who smoked SC products regularly; SC use alleviated cannabis withdrawal, demonstrating cross-tolerance in humans.

### Dependence Liability

**Reward mechanism:** JWH-018 has CB1-dependent reinforcing properties and acutely increases dopaminergic transmission selectively in the NAc shell (Pintori et al. 2021 [Ref 15]).

**Repeated exposure consequences (rodent):** Pintori et al. (2021 [Ref 15]) found repeated JWH-018 caused adaptive changes in mesolimbic and mesocortical dopaminergic pathways plus a neuroinflammatory phenotype — suggesting neuroadaptations that could underlie compulsive use.

**Self-administration:** JWH-018 does not reinstate opioid-seeking in monkeys (Gerak et al. 2019 [Ref 33]), suggesting no synergistic abuse liability with opioids in primates.

**Hyatt & Fantegrossi (2014 [Ref 17]):** In mice, JWH-018 initially produces aversive effects (conditioned taste aversion) in cannabinoid-naïve animals, but prior THC exposure reveals JWH-018's appetitive properties. This suggests cannabis-naive first-time users face higher risk of adverse reactions, while experienced cannabis users may be more susceptible to JWH-018's reinforcing effects.

**Withdrawal:** Clinical reports document SC withdrawal syndrome including: restlessness, irritability, insomnia, nausea, anxiety, and craving (Gunderson et al. 2012 [Ref 18]). No controlled withdrawal study for JWH-018 specifically has been published.

**Brief seed values:**
- Physical dependence: moderate; Psychological: moderate; Formation: moderately addictive with high abuse potential
- These assessments are broadly consistent with the animal literature and clinical case reports, but no human clinical study directly quantifies JWH-018 dependence liability.
- **⚠ FLAG:** Seed dependence values are plausible but not formally validated by controlled human studies.

---

## Interactions

### Opioids

Gerak et al. (2019 [Ref 33]) assessed JWH-018 × µ-opioid agonist interactions in rhesus monkeys:
- JWH-018 did NOT increase remifentanil self-administration preference over opioid alone
- JWH-018 did NOT reinstate heroin-seeking
- JWH-018 did NOT increase opioid potency
- **Conclusion:** No evidence that JWH-018 enhances opioid abuse liability in primates. However, additive CNS depression remains a pharmacodynamic concern in human polydrug use.

### THC / Cannabis / Cannabinoids

Strong cross-tolerance documented (Tai et al. 2015 [Ref 22]). Prior THC exposure attenuates JWH-018 aversive effects and reveals appetitive effects (Hyatt & Fantegrossi 2014 [Ref 17]). Combined use would be expected to produce additive to possibly synergistic CB1 stimulation.

### CYP2C9 / CYP1A2 Inhibitors and Inducers

JWH-018 is primarily metabolized by CYP2C9 and CYP1A2. CYP2C9 inhibitors (e.g., fluconazole, amiodarone, some NSAIDs) could increase JWH-018 plasma levels and toxicity. CYP1A2 inducers (tobacco smoke, omeprazole) would accelerate clearance. CYP2C9 slow metabolizer polymorphisms represent a population-level toxicity risk factor (Chimalakonda et al. 2013 [Ref 3]; Stout & Cimino 2014 [Ref 4]).

### Cocaine, LSD, DMT, Mescaline

The brief lists these interactions as "unknown." No published pharmacological interaction data between JWH-018 and cocaine, LSD, DMT, or mescaline was found in this search. **⚠ FLAG:** All four interactions remain uncharacterized. Given the different primary mechanisms (dopaminergic for cocaine; serotonergic for LSD, DMT, mescaline), additive cardiovascular and psychiatric risks are pharmacologically plausible but not evidenced.

---

## Legal Status

| Jurisdiction | Status | Schedule/Class | Effective Date |
|---|---|---|---|
| USA | Schedule I (CSA) | Schedule I | Temporary: 1 Mar 2011; Permanent: 9 Jul 2012 (via FDASIA) |
| United Kingdom | Controlled | Class B (Misuse of Drugs Act 1971) | 23 Dec 2009 |
| Germany | Controlled | Narcotics Law (BtMG) | January 2009 |
| EU (EMCDDA monitored) | Various national controls | — | From 2009 onward |
| Australia | Controlled | Criminal Code Regulation 2005 | April 2014 |
| Canada | Controlled | CDSA Schedule II (generic naphthoylindole definition) | Unspecified |

[Refs 29, 30, 37, web sources]

Germany was the first jurisdiction globally to schedule JWH-018, and the UK followed within the same year. The US DEA emergency scheduling followed in March 2011 after widespread exposure and adverse event reports.

---

## Clinical Trials

**NCT06044415** — "Brain Activity Under the Influence of JWH"
- Sponsor: Maastricht University (Netherlands)
- Status: UNKNOWN
- Phase: N/A
- Condition studied: Neurotransmission During JWH Intoxication
- This trial is consistent with the Theunissen/Ramaekers group's published studies [Refs 32, 20]

No other registered clinical trials involving JWH-018 were found on ClinicalTrials.gov.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Safety-Critical Flags (require human editorial review)

1. **⚠ LD50 / toxic dose:** No published LD50 or human lethal dose data for JWH-018 in any species. Exact toxic dosage is genuinely unknown. Generation agent should not fabricate or extrapolate values.

2. **⚠ Benzodiazepine seizure management:** Wilson et al. (2019 [Ref 21]) found benzodiazepines ineffective for JWH-018-induced convulsions in mice. This contradicts standard SC toxicity management guidelines that recommend benzodiazepines. Flag for clinical harm reduction text — needs explicit caveat.

3. **⚠ Duration data not human-verified:** Seed data duration values (onset 5–10 min, peak 60–90 min, etc.) are plausible class estimates but no controlled human PK study for smoked JWH-018 has characterized these parameters. Should be labeled as community-derived/class-inferred estimates.

4. **⚠ Tolerance half-life (5 days) not confirmed:** The seed data's 5-day tolerance half-life and 1.5-week full reset are not from a human study; animal data shows tolerance persisting ≥14 days in mice. Source is unclear — possible community consensus. Flag for editorial review.

5. **⚠ Dose range data:** Seed data lists threshold 1 mg, light 1–2 mg, common 2–3 mg, strong 3–5 mg (all smoked). These values are not from a controlled human study — no published dose-response study for smoked JWH-018 in humans exists. These appear to be community consensus values (consistent with reports on harm reduction forums). The Theunissen studies confirm impairment but do not publish a precise dose table. Editorial note should accompany these values.

6. **⚠ Dependence classification:** Brief states "moderate" physical and psychological dependence. This is broadly supported by animal data and clinical case series but not by a formal human clinical study.

### Data Gaps (Information Not Found in Literature)

- **Original Huffman synthesis paper (1994/1995):** The primary publication (likely JMed Chem) was not retrievable via PubMed or OpenAlex. The 2021 Howlett/Thomas/Huffman review [Ref 5] is the best available substitute.
- **Human plasma half-life:** Not published. No controlled PK study in humans for smoked JWH-018.
- **Melting point:** Not found in peer-reviewed sources. PubChem does not provide this value in API output.
- **Specific logP / water solubility values:** Not found in peer-reviewed sources for JWH-018.
- **CYP3A4 / 2D6 involvement:** Minimal contribution (fm < 0.2) confirmed by Chimalakonda 2012 [Ref 2].
- **Stereochemistry / active isomers:** JWH-018 is achiral (no stereocenters); not applicable.
- **Serotonin syndrome risk:** No specific data found. JWH-018 does not directly interact with 5-HT receptors based on available pharmacology; serotonin syndrome risk is not established.
- **Cocaine interaction:** No published data. Brief lists as unknown — confirmed.
- **LSD, DMT, mescaline interactions:** No published data. All three confirmed as unknown.
- **Physical form characterization:** No peer-reviewed melting point or crystalline form data retrieved.

### Contradictions Between Sources

None identified between seed data and published sources for confirmed values. The molecular weight and IUPAC name match. The pharmacological class ("CB1 full agonist") is confirmed and consistent with seed data.

### Structural Analogy Sections

- Seizure management (benzodiazepine caveat) is from JWH-018-specific data, not analog inference.
- Duration and dose data rely on class-level inference and community reports as no human-controlled dose-response studies exist.